Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Peyman Nowrouzi-Sohrabi; Negin Soroush; Reza Tabrizi; Mojtaba Shabani-Borujeni; Shahla Rezaei; Fatemeh Jafari; Mahnaz Hosseini-Bensenjan; Bruno H Stricker; Mandy van Hoek; Fariba Ahmadizar

doi:10.3389/fphar.2021.618208

Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Front Pharmacol. 2021 Mar 29:12:618208. doi: 10.3389/fphar.2021.618208. eCollection 2021.

Authors

Affiliations

¹ Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
² Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
³ Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands.
⁴ Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
⁵ Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
⁶ Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
⁷ Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
⁸ Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
⁹ Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands.

Abstract

Background: Whether liraglutide use improves cardiometabolic risk factors in different subsets of subjects with coronary artery disease (CAD) remains unclear. In a systematic review and meta-analysis, we quantified the effects of liraglutide on cardiometabolic risk profile in subjects with CAD with or without type 2 diabetes mellitus (T2D). Methods: Online database searches were conducted in PubMed, Scopus, EMBASE, Web of Science, Cochrane library, and Google Scholar from incept up to 15th January 2021. We identified randomized controlled trials (RCTs) assessing the effects of liraglutide compared to placebo on cardiometabolic risk profile. We used the random- or fixed-effect models to pool the weighted mean differences (WMDs) and 95% confidence intervals (CIs). Results: Out of a total of 7,320 citations, six articles (seven RCTs) with 294 subjects with CAD (mean age, 61.21 years; 19% women) were included. Our findings presented as WMD and 95% CI showed a statistical significant decrease in hemoglobin A1c (HbA1c) [-0.36%; -0.47; -0.26, p < 0.001; I ² = 0.0% (with 6 RCTs)], body mass index (BMI) [-0.61 kg/m²; -1.21; -0.01, p = 0.047; I ² = 72.2% (with five RCTs)], and waist circumference [-2.41 cm; -3.47; -1.36, p < 0.001; I ² = 0.0% (with three RCTs)]. Through a set of subgroup analyses, we found a significant reduction in BMI in CAD patients with T2D [WMD = -1.06; 95% CI, -1.42, -0.70, p < 0.001; I ² = 0.0% (with three RCTs)] compared to CAD only patients [WMD = -0.08; 95% CI, -0.45, 0.29, p = 0.66; I ² = 0.0% (with two RCTs)] in the liraglutide group compared with the placebo group. No significant changes in heart rate, blood pressure, and lipid profiles were observed. Conclusions: Among people with established CAD, liraglutide significantly improved HbA1c, BMI, and waist circumference values. The effect of liraglutide on BMI was more robust in individuals with T2D compared to those without.

Keywords: cardiometabolic profiles; coronary artery disease; liraglutide; meta-analysis; systematic review.

Publication types

Review